#### **Australian Government**

## Department of Health, Disability and Ageing

Therapeutic Goods Administration

## **Public Summary**

Summary for ARTG Entry: 233205 Folinic Acid

ARTG entry for Medicine Listed

Sponsor FIT-BioCeuticals Pty Ltd

Postal Address Blackmores Limited, PO Box 1725, Warriewood, NSW, 2102

Australia

ARTG Start Date 29/01/2015
Product Category Medicine
Status Active

Approval Area Listed Medicines

#### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

#### **Products**

#### 1 . Folinic Acid

Product Type Single Medicine Product Effective Date 17/09/2025

# Permitted Indications

Helps convert (state food) into energy

Relieve weariness/tiredness/fatigue/feeling of weakness

Aid/assist healthy red blood cell production

Maintain/support healthy immune system function

Helps decrease/reduce homocysteine levels

Aid/assist/helps synthesis of neurotransmitters

Helps maintains/support healthy foetal CNS/brain development

Maintains/support healthy foetal development

# Indication Requirements

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

If directed to women, Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.

Product presentation must not imply or refer to serious immunological diseases.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to chronic fatigue syndrome.

Product presentation must not imply or refer to serious cardiovascular conditions.

#### Standard Indications

No Standard Indications included on Record

#### **Specific Indications**

No Specific Indications included on Record

#### Warnings

No Warnings included on Record

#### **Additional Product information**

## Page 1 of 2



# Australian Government

# Department of Health, Disability and Ageing

Therapeutic Goods Administration

Pack Size/Poison information

Pack Size Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

**Visual Identification** 

**Active Ingredients** 

calcium folinate.6944 mgEquivalent: folinic acid.5 mg

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate

colloidal anhydrous silica

croscarmellose sodium

hypromellose

liquid paraffin

magnesium stearate

microcrystalline cellulose

purified water

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.